Taldefgrobep alfa manufacturers
|
| | Taldefgrobep alfa Basic information |
| | Taldefgrobep alfa Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Taldefgrobep alfa Usage And Synthesis |
| Uses | Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research[1][2]. | | in vivo | Taldefgrobep alfa (2 mg/kg; iv or sc; single dose) has rapid plasma clearance after intravenous administration in mice, but slow absorption (Tmax=24 h) after subcutaneous administration with Cmax=15.4 mg/mL and bioavailability (F)=84%[1]. | | References | [1] Zhu Y, et al. LC-MS/MS multiplexed assay for the quantitation of a therapeutic protein BMS-986089 and the target protein Myostatin. Bioanalysis. 2016 Feb;8(3):193-204. DOI:10.4155/bio.15.238
[2] Straus M. 2023 Pipeline Report: Testing the Limits[J]. Pharmaceutical Executive, 2022, 42(12). |
| | Taldefgrobep alfa Preparation Products And Raw materials |
|